Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the I...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Phillips, Kelly-Anne, Milne, Roger L., Rookus, Matti A., Daly, Mary B., Antoniou, Antonis C., Peock, Susan, Frost, Debra, Easton, Douglas F., Ellis, Steve, Friedlander, Michael L., Buys, Saundra S., Andrieu, Nadine, Noguès, Catherine, Stoppa-Lyonnet, Dominique, Bonadona, Valérie, Pujol, Pascal, McLachlan, Sue Anne, John, Esther M., Hooning, Maartje J., Seynaeve, Caroline, Tollenaar, Rob A.E.M., Goldgar, David E., Beth Terry, Mary, Caldes, Trinidad, Weideman, Prue C., Andrulis, Irene L., Singer, Christian F., Birch, Kate, Simard, Jacques, Southey, Melissa C., Olsson, Håkan L., Jakubowska, Anna, Olah, Edith, Gerdes, Anne-Marie, Foretova, Lenka, Hopper, John L.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753701/
https://ncbi.nlm.nih.gov/pubmed/23918944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.8313
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares